Nutrient stress that produces quiescence and catabolism in normal cells is lethal to cancer cells, because oncogenic mutations constitutively drive anabolism. One driver of biosynthesis in cancer cells is the mammalian target of rapamycin complex 1 (mTORC1) signaling complex. Activating mTORC1 by deleting its negative regulator tuberous sclerosis complex 2 (TSC2) leads to hypersensitivity to glucose deprivation. We have previously shown that ceramide kills cells in part by triggering nutrient transporter loss and restricting access to extracellular amino acids and glucose, suggesting that TSC2-deficient cells would be hypersensitive to ceramide. However, murine embryonic fibroblasts (MEFs) lacking TSC2 were highly resistant to ceramide-induced death. Consistent with the observation that ceramide limits access to both amino acids and glucose, TSC2
INTRODUCTION
The mammalian target of rapamycin complex 1 (mTORC1) signaling complex containing the serine/threonine kinase mTOR is active in many cancers where it promotes protein, lipid and nucleotide biosynthesis.
1,2 mTORC1 is also activated in tuberous sclerosis, a relatively common disease (1 in 6000 births 3 ) characterized by the growth of benign tumors (hamartomas) in multiple organs. Tuberous sclerosis is caused by heterozygous mutations in the genes encoding either tuberous sclerosis complex 1 (TSC1) or tuberous sclerosis complex 2 (TSC2). The TSC1 and TSC2 proteins form a complex with TBC1D7 that negatively regulates mTORC1 4 (reviewed in Yecies et al. 2 and Huang et al. 5 ) TSC2 is the GTPase activating protein for Rheb, a GTPase that has an essential role in the activation of mTORC1 by both growth factors and amino acids. Elevated mTORC1 signaling in TSC-deficient cells confers hypersensitivity to glucose withdrawal. 6, 7 mTOR-driven anabolism sensitizes these cells to glucose restriction, and rapamycin protects TSC2 À / À murine embryonic fibroblasts (MEFs) from death upon glucose withdrawal. These results suggest that mTOR hyperactivation in malignant tumor cells might confer sensitivity to nutrient stress.
Ceramide has been called a 'tumor suppressor lipid' based on its ability to slow cellular proliferation, induce differentiation and trigger cell death. 8 Our group recently demonstrated that ceramide kills mammalian cells in part by downregulating both amino acid and glucose transporters proteins, thereby restricting cellular access to extracellular nutrients. 9 This finding suggested that sphingolipid drugs might be used to starve constitutively anabolic cancer cells to death while inducing quiescence and catabolism in normal cells. In fact, a water-soluble sphingolipid, FTY720, also triggers nutrient transporter loss and selectively kills highly anabolic cells. 10 At higher doses than are required for its actions on sphingosine 1-phosphate receptors, FTY720 has antineoplastic activity in vitro and in vivo. As FTY720 analogs that lack its doselimiting toxicity retain FTY720's effects on nutrient transporter proteins and its antineoplastic activity, FTY720 analogs have the potential to be safe and effective cancer therapies that selectively starve cancer cells to death. Given ceramide's important role in tissue homeostasis and the therapeutic potential of related sphingolipid drugs, identifying the oncogenic mutations that confer sensitivity and resistance to sphingolipid-induced nutrient transporter loss and death will provide insights into growth control, tumor initiation and progression, and the mechanisms of resistance to cancer therapies.
Because mTORC1-driven anabolism sensitizes TSC2 À / À MEFs to glucose depletion, 6, 7 we hypothesized that these cells would also be hypersensitive to sphingolipid-induced nutrient transporter loss. In striking contrast to this prediction, TSC2
À / À MEFs maintained their hyperactive mTORC1 signaling, but were protected from ceramide-induced death. This result led to the discovery that, under some conditions, activated mTORC1 can promote an adaptive cellular response to nutrient restriction.
RESULTS
Loss of TSC2 confers resistance to ceramide and nutrient deprivation Consistent with published reports, 6, 7 TSC2 À / À MEFs died faster than their TSC2 þ / þ counterparts when deprived of glucose ( Figure 1a ). As ceramide downregulates the broadly expressed glucose transporter GLUT1, 9 we expected that TSC2 À / À MEFs would also be hypersensitive to C 2 -ceramide, a form of this sphingolipid that is converted to the physiological long-chain version within cells. 11, 12 Surprisingly, TSC2 À / À MEFs were highly resistant to ceramide-induced death relative to TSC2 þ / þ controls (Figure 1b) . TSC2
À / À MEFs were also protected from death triggered by FTY720, a related sphingolipid that also produces starvation secondary to nutrient transporter loss 10 ( Figure 1c ). TSC2
À / À MEFs were, however, hypersensitive to staurosporineinduced death (Figure 1d ) consistent with published data 13 , suggesting that the resistance of TSC2 À / À MEFs to sphingolipids was specific. Ceramide and FTY720 downregulate both glucose and amino acid transporters. 9, 10 To mimic the partial nutrient transporter loss induced by ceramide and FTY720, cells were transferred to Dulbecco's modified Eagle medium (DMEM) containing 1% the normal amount of amino acids and glucose. Combined restriction of amino acids and glucose killed cells with faster kinetics than glucose restriction alone (Figure 1e ). However, TSC2
À / À MEFs were resistant to combined amino acid and glucose restriction relative to TSC2 þ / þ controls. Together, these findings suggest that TSC2
À / À MEFs have a survival advantage under some forms of nutrient stress.
TSC2
À / À MEFs are resistant to nutrient deprivation despite the sustained activation of mTORC1 Amino acid withdrawal rapidly inactivates mTORC1 (reviewed in Jewell et al.
14 and Yuan et al. 15 ). Rag GTPases regulate mTORC1 activity by controlling its localization to the lysosome, where it is activated by the Rheb GTPase. 16, 17 Glucose limitation, on the other hand, reduces mTORC1 via AMP-activated protein kinase (AMPK)-dependent phosphorylation of TSC2 and Raptor. 7, 18 We tested whether limiting glucose and amino acids was sufficient to inhibit mTORC1 in TSC2 À / À MEFs by monitoring the mTORC1-specific phosphorylation site in p70S6 kinase, Thr389 and the p70S6 kinase-dependent sites in the ribosomal S6 protein, serines 240 and 244. 19, 20 mTORC1 was rapidly inactivated in TSC2 þ / þ MEFs transferred to medium containing 1% the normal level of amino acids and glucose, but mTORC1 remained active in TSC2 À / À MEFs (Figures 2a-c) . In fact, p70S6K Thr389 phosphorylation in nutrientrestricted TSC2
À / À MEFs exceeded that present in TSC2
MEFs in complete medium at all time points examined ( Figure 2b ). As expected, ceramide treatment reduced mTORC1 signaling in TSC2 þ / þ MEFs (Figures 2d-f ). mTORC1 signaling in TSC2
MEFs was, however, resistant to inhibition by ceramide. TSC2
MEFs exhibited higher Thr389 and S6 phosphorylation in the presence of ceramide than was seen in TSC2 þ / þ MEFs in control medium at all time points examined (Figures 2e and f) . The partial decrease in the phosphorylation of p70S6K in TSC2
À / À MEFs treated with ceramide ( Figure 2e ) might be due to ceramideinduced nutrient transporter loss 9 or to protein phosphatase 2A activation by ceramide. 21 The mTOR kinase inhibitor PP242 eliminated mTORC1 activity in both genotypes, confirming that these phosphorylations are mTORC1-dependent. Thus, TSC2
MEFs are resistant to death induced by sphingolipids or nutrient deprivation despite sustained mTORC1 activity.
Activation of p70S6K triggers a negative feedback loop that reduces Akt phosphorylation. [22] [23] [24] As p70S6K activity declined slightly in ceramide-treated TSC2 À / À MEFs (Figures 2d-f) , we determined whether the loss of negative feedback might increase Akt activation. Consistent with reports that ceramide inhibits Akt, 25, 26 þ / þ and TSC2 À / À MEFs are compared using a t-test.
maintenance of mTORC1 activity (Figures 2d-f) , this was not altered by ceramide. TSC2 serves as the GTPase activating protein for Rheb, a GTPase required for mTORC1 activation by all stimuli.
14 When expressed at high levels, activated mutants of Rheb maintain mTORC1 activity in the absence of amino acids. 17 However, under our experimental conditions, Rheb-Q64L expression did not maintain mTORC1 activity, most likely due to insufficient overexpression (Figure 2h ). To confirm that the resistance of TSC2 À / À MEFs was due to the loss of TSC2, we knocked down TSC2 using a previously validated short hairpin RNA. 27 Two independent MEF lines (referred to as A and B) were transduced to rule out cell line-specific effects. Similar to the TSC2 À / À MEFs (Figure 2 ), MEF lines with TSC2 knockdown exhibited sustained phosphorylation of p70S6K at Thr389 and of ribosomal protein S6 at serines 240/244 following nutrient deprivation (Figures 3a and b) . MEFs expressing short hairpin RNA against TSC2 were again resistant to death following combined glucose and amino acid deprivation despite their sustained mTORC1 signaling ( Figure 3c ). As a complimentary approach, we also re-expressed TSC2 in TSC2 À / À MEFs. Following the introduction of TSC2, mTORC1 activity declined in nutrient deprived or ceramide-treated TSC2 À / À MEFs similar to TSC2 The results of (a) were quantified and the signal from phosphorylated p70S6K (left) or ribosomal S6 (right) was expressed relative to the total protein and normalized to the control TSC2 þ / þ sample. (c) The TSC2 knockdown MEF lines used in (a) were maintained in 1% nutrients for 24 h and viability measured by vital dye exclusion and flow cytometry. In (b, c), means ±s.e.m. are shown for three independent experiments. *Po0.05 and **Po0.01 when matched shLuc and shTSC2 MEF lines are compared using a t-test. (d) TSC2
À / À MEFs stably expressing empty vector or human TSC2 were maintained in normal DMEM, treated with 20 mM ceramide or transferred to 1% nutrient medium for 6 h. mTORC1 signaling was evaluated by western blot using a LI-COR Odyssey imager. (e) The results of (d) were quantified and the signal from phosphorylated p70S6K (left) or ribosomal S6 (right) was expressed relative to the total protein and normalized to the control TSC2 À / À þ vector sample. The means from two independent experiments are shown. (f ) TSC2 þ / þ , TSC2 À / À and TSC2 À / À þ vector MEFs reconstituted with TSC2 were treated with 20 mM ceramide and viability measured at the indicated time points. The averages of 3-4 independent experiments are shown ±s.e.m. *Po0.05 and **Po0.01 when TSC2
À / À þ vector and TSC2 À / À MEFs þ TSC2 are compared using a t-test.
control MEFs (Figures 3d and e) . The sensitivity of TSC2 À / À MEFs to ceramide-induced death was similarly restored by reconstitution with TSC2 ( Figure 3f ). Finally, TSC2
À / À MEFs may have reduced mTORC2 activity. 28 In yeast, TORC2 regulates ceramide metabolism. 29 However, Rictor À / À MEFs that completely lack mTORC2 30 were as sensitive to ceramide and nutrient restriction as Rictor þ / þ controls (data not shown).
Together, these studies demonstrate that the resistance of TSC2 À / À MEFs to nutrient stress is due to the deletion of TSC2.
Elevated mTORC1 signaling facilitates the adaptive upregulation of transporters following nutrient deprivation TSC2 À / À MEFs maintain elevated mTORC1 signaling even in the presence of ceramide (Figures 2d-f) . As mTORC1 activation can prevent nutrient transporter downregulation in growth factor withdrawn cells, 31, 32 we tested whether sustained mTORC1 activity in TSC2 À / À MEFs prevented ceramide-induced nutrient transporter loss. While loss of TSC1 or TSC2 leads to amino acid permease trafficking defects in yeast, 33 the 4F2hc expression pattern was similar in TSC2 þ / þ and TSC2 À / À MEFs (Figure 4a ). Ceramide downregulated 4F2hc with equal efficiency in both TSC2 þ / þ and TSC2 À / À MEFs (Figure 4b ). However, after 6 h, 4F2hc surface levels rebounded selectively in TSC2 À / À MEFs, eventually exceeding baseline levels. Similar results were obtained in cells treated with FTY720 (data not shown). When TSC2 À / À MEFs were reconstituted with TSC2, nutrient transporters were no longer restored to the cell surface after ceramide treatment, demonstrating that this response stems from the deletion of TSC2 (Figure 4c) . Thus, although transporters were downregulated similarly by ceramide in MEFs of both genotypes, the effect is temporary in TSC2 À / À MEFs. þ / þ and TSC2 À / À MEFs were treated with or without rapamycin and ceramide as indicated and viability measured at 24 h by flow cytometry. *Po0.05, **Po0.01 when using a t-test.
The results in Figure 4b suggest that the survival advantage of ceramide-treated TSC2 À / À MEFs might stem from increased access to extracellular nutrients. To test this idea, we measured amino acid uptake in MEFs treated with ceramide and pulsed with 3 H-labeled amino acids for the final 2 h before lysis. Consistent with surface amino acid transporter levels (Figure 4b ), amino acid uptake was not different in TSC2
þ / þ and TSC2 À / À MEFs between 3 and 5 h after ceramide addition (Figure 4d ). However, amino acid uptake was higher in TSC2
À / À MEFs than in TSC2
þ / þ controls between 10 and 12 h after ceramide addition when 4F2hc surface levels had rebounded in TSC2 À / À , but not TSC2 þ / þ MEFs (Figures 4b and d). 2-aminobicyclo-(2,2,1 )-heptane-2-carboxylic acid (BCH) is a selective, competitive inhibitor of 4F2hc-dependent amino acid import. 34, 35 BCH alone was not toxic (Figure 4e ). However, BCH reduced the survival of TSC2
À / À MEFs treated with ceramide. Taken together, these results suggest that the resistance of TSC2 À / À MEFs to ceramide-induced death stems in part from their ability to restore access to extracellular nutrients.
To confirm that the restoration of transporters following ceramide treatment was mTORC1-dependent, we determined the effect of rapamycin on transporter expression levels. Rapamycin alone slightly decreased surface 4F2hc levels in both TSC2-wildtype and knockout MEFs (Figure 4f ). When ceramide and rapamycin were combined, the rebound in 4F2hc expression seen in ceramide-treated TSC2
À / À MEFs no longer occurred. The restoration of 4F2hc surface levels in TSC2
À / À MEFs following ceramide treatment thus depends on mTORC1 activity. mTORC1 promotes protein translation. Although blocking protein translation with cycloheximide had no effect on 4F2hc levels in the absence of ceramide (Figure 4f ), 4F2hc levels were further reduced in TSC2
þ / þ MEFs, and 4F2hc levels no longer rebounded in TSC2 À / À MEFs when cycloheximide and ceramide were combined. Together, these results suggest that mTORC1-dependent new protein synthesis restores surface amino acid transporter levels after sphingolipid-induced downregulation in TSC2
MEFs. If restoration of surface transporters contributes to the survival of TSC2 À / À MEFs, then rapamycin might be expected to reduce the survival of TSC2
À / À MEFs treated with ceramide. However, rapamycin protects cells from ceramide treatment 9 and from nutrient stress 6, 7 by limiting nutrient demand. In fact, rapamycin increased the survival of ceramide-treated TSC2 þ / þ MEFs (Figure 4g ). At the same time, rapamycin eliminated the survival advantage of TSC2 À / À MEFs. Together, these findings are consistent with a model where nutrient access and bioenergetic demand define cellular sensitivity to ceramide.
Ceramide downregulates nutrient transporter proteins but does not increase their degradation. 9 Consistent with this, total cellular levels of 4F2hc were not decreased by ceramide (Figure 5a ). In fact, although surface levels of 4F2hc decreased (Figure 4b ), the total cellular levels of 4F2hc were increased by ceramide in both TSC2 þ / þ and TSC2 À / À MEFs (Figure 5a ). The increase in total 4F2hc was enhanced in TSC2 À / À MEFs and rapamycin dependent. Total 4F2hc levels might increase in ceramide-treated cells as part of an adaptive response to nutrient stress caused by transporter downregulation. Under nutrient stress, both yeast and mammalian cells synthesize new transporters to increase uptake capacity. We tested whether 4F2hc was adaptively upregulated in response to nutrient stress. After 24 h of nutrient limitation, TSC2 þ / þ MEFs exhibited a mild but statistically significant increase in 4F2hc expression levels to 120% control (Figure 5b) . In TSC2 À / À MEFs, the adaptive upregulation of transporter proteins was greatly enhanced; 4F2hc levels rose to 180% control. A similar response was observed in TSC2 knockdown MEF lines A and B (Figure 5c ). Rapamycin, the mTOR kinase inhibitor PP242, and cycloheximide blocked the dramatic upregulation of 4F2hc in nutrient-stressed TSC2 À / À MEFs, normalizing the responses of TSC2 þ / þ and TSC2 À / À MEFs (Figure 5b ). AMPK is activated under low glucose conditions and has a key role in the adaptive response to nutrient stress by limiting anabolism and promoting catabolism. AMPK is hyperactivated in TSC2 À / À MEFs ( 36,37 and data not shown). The AMPK inhibitor compound C 38 did not diminish 4F2hc upregulation under nutrient stress in TSC2 þ / þ or TSC2 À / À MEFs (Figure 5b ). In fact, compound C treatment slightly enhanced 4F2hc upregulation, possibly by eliminating AMPK's ability to inhibit mTORC1. Given the results in Figures 5a-c , an enhanced adaptive response to nutrient stress is a plausible explanation for the suprabasal levels of surface 4F2hc in TSC2
MEFs after 12 h of ceramide treatment (Figures 4b, c and f) .
As TSC2 À / À MEFs are resistant to sphingolipids that downregulate both amino acid and glucose transporters (Figures 1b  and c) , 9 we next evaluated glucose transporter levels in nutrient stressed TSC2 À / À MEFs. As for 4F2hc (Figure 5b ), surface GLUT1 levels were upregulated robustly in nutrient stressed TSC2 (Figure 5d ). Adaptive upregulation of GLUT1 occurred selectively in response to glucose restriction; amino acid limitation did not increase GLUT1 levels. After 12 h of treatment, ceramide also triggered an enhanced adaptive upregulation of GLUT1 in TSC2 À / À MEFs (Figure 5e ). This enhanced GLUT1 expression led to elevated glucose uptake in ceramide-treated TSC2 À / À MEFs relative to controls (Figure 5f ). In summary, TSC2 deletion enhanced the adaptive upregulation of both amino acid and glucose transporters in response to nutrient stress and increased cellular access to extracellular nutrients in the presence of ceramide.
The GCN2 (general control nonderepressible 2) kinase is a key regulator of the cellular response to nutrient stress. 39 Amino acid limitation leads to reduced tRNA charging. Uncharged tRNAs bind and activate the GCN2 kinase that phosphorylates eukaryotic initiation factor 2 (eIF2a). When eIF2a is phosphorylated, the overall rate of translation declines, but several transcripts are translated at a higher efficiency, including the mRNA for the ATF4 (activating transcription factor 4) transcription factor. Increased ATF4 protein level leads to an adaptive response to amino acid limitation that includes the transcription of amino acid transporter genes such as 4F2hc. [40] [41] [42] [43] [44] eIF2a phosphorylation in response to ER stress is altered in TSC2 À / À MEFs. 45 However, eIF2a phosphorylation and ATF4 induction was similar in TSC2 þ / þ and TSC2 À / À MEFs limited for extracellular nutrients (Figures 6a-c) . These results suggest that increased nutrient transporter levels in nutrient-stressed TSC2 À / À MEFs do not stem from differences in eIF2a activity. However, 4F2hc mRNA abundance was significantly increased in nutrientlimited TSC2
À / À MEFs relative to controls (Figure 6d ). Ceramide treatment produced similar changes (Figure 6e) . In both conditions, the increase in 4F2hc mRNA in TSC2 À / À MEFs was inhibited by rapamycin ( Figure 6f ). These results suggest that the enhanced, adaptive 4F2hc upregulation in TSC2 À / À MEFs relative to TSC2
MEFs is a consequence of mTORC1-driven increases in mRNA abundance and translation. Reports indicate that TSC2 À / À MEFs fail to induce autophagy normally due to the constitutive activation of mTORC1. 46, 47 Autophagy provides an important source of nutrients when access to extracellular nutrients is limiting. Given their enhanced ability to synthesize new transporters under nutrient stress, we evaluated autophagy in TSC2 À / À MEFs under our experimental conditions. Autophagosome turnover (autophagic flux) can be assessed by comparing the abundance of proteins degraded by autophagy in the presence and absence of inhibitors of lysosomal degradation. 48 LC3-II present on the inner autophagosomal membrane is degraded along with autophagosomes, and the ratio of LC3-II levels þ / À chloroquine is one measure of autophagic flux. In normal growth medium, we found that TSC2 À / À MEFs had a slightly elevated rate of autophagic flux consistent with a higher basal level of bioenergetic stress secondary to mTORC1 activation (Figures 6g and h) . When shifted to low nutrient medium, TSC2
À / À and TSC2 þ / þ MEFs increased the rate of autophagy to a similar extent. Thus, under our experimental conditions, TSC2 À / À MEFs are able to engage in productive autophagy despite constitutive activation of mTORC1.
Transforming mutations eliminate the resistance of TSC2
MEFs to ceramide
The resistance of TSC2-deficient cells to extracellular nutrient deprivation and sphingolipid-induced death despite elevated mTORC1 activity suggests that mTORC1 may protect nutrientlimited cells under some conditions. Given that ceramide metabolism is altered in many cancers and our interest in developing sphingolipid-based chemotherapeutics that target nutrient transporter proteins, we assessed whether transformed cells could be rendered resistant to sphingolipid-induced nutrient transporter loss by deleting TSC2. Oncogenic, activated H-RasG12V was introduced via retroviral transduction. þ / þ and TSC2 À / À MEFs were incubated in medium containing 5% the normal amount of amino acids and glucose for 24 h and surface 4F2hc levels measured by flow cytometry. This degree of nutrient stress does not trigger cell death but causes cell cycle arrest. Where indicated, rapamycin (100 nM), PP242 (2.5 mM), cycloheximide (CHX, 50 mg/ml), or compound C (comp C, 10 mM) were present during the 24-h treatment. (c) 4F2hc surface levels in wild-type MEF lines stably expressing shRNA against luciferase or TSC2 after 12 h in 1% nutrient medium.
þ / þ and TSC2 À / À MEFs were incubated in medium containing either 1% or 5% the normal amount of amino acids and glucose, 1% glucose, or 1% the normal amount of amino acids and surface levels of GLUT1 measured by flow cytometry at 12 h. (e) As in (d), but cells were treated with ceramide for 12 h. (f ) TSC2 þ / þ and TSC2 À / À MEFs treated with ceramide for 12 h before 2-deoxy-glucose uptake was measured. In all panels, averages of 3-13 independent experiments are shown ± s.e.m. NS, not significant (P40.05); *Po0.05; and **Po0.01 using a t-test to compare the indicated samples.
H-RasG12V-dependent signaling was detrimental (Figure 7d) . A potential explanation for these results was that Ras increases metabolic demand by driving anabolism. Consistent with this idea, H-RasG12V-expression normalized ATP levels in ceramide-treated À / À MEFs were maintained in 1% nutrient medium for the indicated interval. eIF2a and mTORC1 signaling was evaluated by western blot using a LI-COR Odyssey imager. Thapsigargin (2 mM, TG) was used as a positive control for eIF2a activation. (b, c) eIF2a phosphorylation was quantified and expressed relative to total eIF2a (b); total ATF4 levels were also quantified (c). Values were normalized to the signal in untreated TSC2
þ / þ samples and the averages of three independent experiments plotted ± s.e.m. (d, e) mRNA was isolated from TSC2 þ / þ or TSC2 À / À MEFs maintained in standard medium and DMEM containing 1% nutrients (d) or 15 mM ceramide (e). 4F2hc mRNA levels were measured using quantitative RT-PCR and expressed relative to actin mRNA. (f ) As in (d, e) except that 100 nM rapamycin (rap) was added where indicated; 1% nutrient treatment was for 8 h, ceramide treatment was for 12 h. (g, h) TSC2 þ / þ and TSC2 À / À MEFs were maintained in 1% nutrient medium for 3 h in the presence or absence of 25 mM chloroquine (CQ) and LC3-II levels measured by western blotting. A representative blot is shown (g); average ratios of LC3-II intensity þ / À chloroquine are plotted ±s.e.m. as a measure of autophagic flux. In all panels, average results of 3 independent experiments are shown ± s.e.m. *Pp0.05; **Pp0.01. In 6f, P ¼ 0.37 when comparing 1% nutrients þ / À rapamycin.
Together, these experiments suggest that TORC1-driven adaptive nutrient transporter upregulation in TSC2
À / À MEFs depends on both nutrient transporter upregulation and the conservation of resources due to the silencing of parallel anabolic pathways.
DISCUSSION
These results suggest a novel, adaptive role for mTORC1 signaling in non-transformed cells during extracellular nutrient limitation or sphingolipid-induced nutrient transporter loss (Figure 8 ). Nutrient deprivation initiates an adaptive response that includes transporter upregulation. 40, [42] [43] [44] We demonstrated that the adaptive upregulation of two transporters, 4F2hc and GLUT1, is dramatically enhanced in nutrient stressed TSC2 À / À MEFs (Figures 4 and 5) . Although reagents are not currently available to quantify their surface levels by flow cytometry, it is likely that other nutrient transporters are similarly affected. This increased nutrient transporter expression provides a potential explanation for the increased survival of TSC2
À / À MEFs, as it would provide greater access to extracellular nutrients (Figures 4d   and 5f ). Consistent with this model, BCH significantly reduced the survival advantage of TSC2 À / À MEFs over TSC2 þ / þ controls despite the fact that it only inhibits a subset of amino acid transporters (Figure 4e) . Interestingly, TSC2
À / À MEFs are also better able to adapt to hypoxia. Under hypoxia, TSC2
À / À MEFs exhibit a more sustained accumulation of Hif-1a target gene mRNA and a higher rate of protein translation conferring resistance to death and allowing increased cell accumulation. 49, 50 Thus, TSC2 À / À MEFs have an advantage under two forms of metabolic stress, hypoxia and combined glucose and amino acid limitation, because they are better able to execute an adaptive response that depends on protein translation (Figures 4f  and 5b) .
It is frequently stated that amino acids regulate mTORC1 signaling independent of TSC2. [51] [52] [53] However, amino acid deprivation does not eliminate mTORC1 signaling in TSC2
MEFs unless serum is first withdrawn 16, [54] [55] [56] (reviewed in Huang et al., 5 ( Figures 2a-c) ). In our study, nutrient deprivation was performed in the presence of normal serum to restrict the stresses placed on cells to only amino acid and glucose limitation. Like þ / þ or TSC2 À / À MEFs expressing empty vector or oncogenic Ras were treated with 20 mM ceramide for 12 h and ATP levels were measured. (f) As in (e), but surface 4F2hc levels measured by flow cytometry. In all panels, averages of at least three independent experiments are shown ±s.e.m. NS, not significant (P40.05); *Po0.05; and **Po0.01 when the indicated samples were compared using a t-test. In panel e, when TSC2 þ / þ and TSC2 À / À vector cells were compared with a t-test, P ¼ 0.16; for Ras-expressing cells P ¼ 0.83. ceramide treatment, this nutrient restriction protocol did not eliminate cellular access to glucose and glutamine, but did produce sufficient nutrient stress to rapidly silence mTORC1 (Figures 2a and 6a) . Similar to our results in TSC2-deficient MEFs (Figures 2a-c, Figures 3a and b) , TSC2 knockdown in amino acid-restricted Drosophila S2 cells also maintains p70S6K Thr389 phosphorylation 57 , suggesting an evolutionarily conserved role for TSC2 in response to amino acid limitation. At the same time, the Rag GTPases have a central role in linking mTORC1 activity to amino acid levels by controlling the localization of mTORC1 to lysosomes. 16, 17, 58 However, the loss of TSC2 (Figures 2a-c) or the overexpression of Rheb or Rheb-GTP maintains mTORC1 activity without retaining mTORC1 on the lysosome. 16, 17, [59] [60] [61] In the case of Rheb overexpression, this result has been hypothesized to reflect Rheb and mTORC1 colocalization to non-lysosomal membranes; colocalization of Rheb and mTORC1 on non-lysosomal membranes is sufficient to maintain mTORC1 activity in the absence of amino acids.
17 TSC2 loss might also promote the association of Rheb and mTORC1 on a non-lysosomal membrane. As prior serum withdrawal eliminates mTORC1 activity in amino acid restricted TSC2 À / À MEFs, 55 serum may regulate the association of Rheb and mTORC1 at this non-lysosomal site through a TSC2-independent mechanism. Antibodies that recognize endogenous Rheb in immunofluorescence microscopy experiments will be important tools to understand how mTORC1 activity is maintained in nutrient-stressed TSC2 À / À MEFs without lysosomal localization.
The resistance of TSC2-deficient cells to ceramide-induced death may provide insight into the pathogenesis of the benign hamartomas that form in tuberous sclerosis patients. Ceramide has been deemed a 'tumor suppressor lipid' due its key role in maintaining tissue homeostasis; 8 the ability to circumvent ceramide-enforced growth limits could help to explain the nonhomeostatic growth of TSC1/2-null hamartomas. Intriguingly, hamartomas in tuberous sclerosis patients do not progress to malignant cancers. 3 The feedback inhibition of Akt-dependent signaling is likely to partially explain this finding. 5, [22] [23] [24] Another potential explanation for the lack of progression to malignancy is that TSC2 loss creates a cellular environment unfavorable to the acquisition of the additional mutations necessary for malignant progression. For example, the loss of TSC2 makes cells dependent on the tumor suppressor protein Rb under metabolic stress 62 and loss of p27 increases apoptosis in the renal tumors that form in TSC2 þ / À mice. 36 Consistent with these reports, we found that the introduction of oncogenic Ras restored the sensitivity of TSC2 À / À MEFs to ceramide (Figure 7a ). The idea that loss of TSC2 is poorly compatible with the accumulation of oncogenic mutations is also consistent with the observation that few human cancers lack the TSC proteins. It is probably significant that the sustained mTORC1 activity in TSC2 À / À MEFs did not prevent proliferative arrest in low nutrient medium (data not shown). The bioenergetic savings associated with cell cycle arrest would ostensibly counterbalance the costs of mTORC1-driven transporter production; oncogenic mutations might eliminate the ATP reserves necessary for mTORC1-dependent adaptations in part by interfering with cell cycle arrest. In conclusion, we have defined a new, adaptive role for mTORC1 signaling in metabolically stressed cells providing novel insights into the pathogenesis of tuberous sclerosis and how oncogenes sensitize cancer cells to therapeutic strategies that target cancer bioenergetics. Figure 8 . Model for the resistance of TSC2 À / À MEFs to nutrient stress. Loss of surface nutrient transporter proteins or extracellular nutrient limitation produces nutrient stress. In wild-type MEFs, mTORC1 is inactive and the limited adaptive response is insufficient to relieve the nutrient stress, eventually leading to cell death. In TSC2 À / À MEFs, in contrast, an enhanced adaptive upregulation of nutrient transporters occurs via mTORC1-driven translation and possibly transcription. In the absence of oncogene-driven anabolism, the resulting increase in nutrient uptake is sufficient to protect TSC2 À / À MEFs from death. When oncogenic Ras increases nutrient demand and/or reprograms metabolism, nutrient transporter upregulation is compromised and the survival advantage of TSC2 À / À MEFs is lost.
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